3 Reasons This Biotech Stock Could Double in 2019

Theratechnologies Inc. (TSX:TH) is the hands-down choice of investors in the biotech industry. The stock is primed for exponential growth in the coming months.

| More on:

Many investors have realized hefty windfalls from biotech stocks. There is always a pot of gold whenever the FDA grants approvals for new drug applications (NDAs). However, investing in this industry is risky business too. Obtaining approval is dependent on clinical trial success, which is a hit-or-miss thing.

Lately, Montreal-based Theratechnologies (TSX:TH) has appeared on investors’ radars. Market analysts have adjusted their forecasts. The price target is a high of $17.25, which represents roughly a 115% climb from its current price of $8.02. But what does this $616.7 million company have to merit such lofty expectations?

Evaluating biotech stocks

First and foremost, you need to look into the research areas the biotech firm is focused on. Usually, a drug to treat cancer, diabetes, heart, or neurological diseases, and other debilitating illnesses shape the destiny of the company. A life-altering technology can also push the company to prominence in the healthcare sector.

The next yardstick is the pipeline or the drug candidates with potential. Companies with more than one product in clinical trials always gain the advantage. But in some cases, having products in various stages of development is detrimental. The biotech can have multiple pathways to success or be spread out too thinly.

Share prices of biotech firms skyrocket whenever the products are in the late stages of R&D and nearing FDA approval. A testing failure can lead to a sell down. But if there is rebound potential during re-testing, a biotech firm can survive the backlash. Once a drug is successfully launched, profitability is assured for years on end.

Strong revenue growth

Theratechnologies’s president and CEO Luc Tanguay is overly optimistic after the excellent start in 2019: “Revenues are almost double what they were at the same time last year. We are more active than ever in the U.S. to support our two products. We are also preparing for the potential launch of Trogarzo in Europe which may represent a sizeable future source of revenues.”

The company reported record first-quarter net sales of $20.1 million in Q1 2019, which is 86% better than the same quarter last year. From a negative EBITDA of $2 million in Q1 2018, the company managed to turn it around and reflect a positive EBITDA of $2 million in the Q1 2019.

Strong cash position

In terms of cash position, the company stands on solid ground with $70.9 million cash as of February 28, 2019. The lead products, Egrifta (tesamorelin) and Trogarzo (ibalizumab), are the income generators. Both are no longer in clinical testing stages but are widely accepted drugs worldwide.

The former is for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The latter is for the treatment of multi-drug-resistant HIV-1 patients. And the sales of these top two drugs are rising dramatically.

Given the high scorecard of Theratechnologies, the market analysts can’t be faulted to anticipate the stock’s meteoric rise in the months ahead.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Investing

Stacked gold bars
Metals and Mining Stocks

B2Gold: Buy, Sell, or Hold in July 2025?

B2Gold has churned out positive news so far in July. Here's how I'd "trade" the TSX gold stock this month.

Read more »

woman checks off all the boxes
Dividend Stocks

CPP Collectors: Here Are 3 More Red Flags the CRA is Watching

Worried about the CRA? Stop immediately by taking these steps and investing wisely.

Read more »

Financial analyst reviews numbers and charts on a screen
Stocks for Beginners

1 Stellar Canadian Stock Down 47% From Its All-Time High to Buy and Hold Forever

Down sharply from its peak, this top Canadian stock is setting itself up for a long-term comeback backed by a…

Read more »

some REITs give investors exposure to commercial real estate
Stocks for Beginners

A 3.4% Dividend Yield? I’m Buying This Dividend Darling and Holding for Decades

Grab this dividend yield while it lasts, and never worry again while holding the top choice on the market!

Read more »

Person holding a smartphone with a stock chart on screen
Dividend Stocks

This 7.4% Dividend Stock Is My Top Pick for Immediate Income

With a solid 7.4% dividend yield, a proven history of dividend growth, and strong fundamentals, it offers both stability and…

Read more »

Hand Protecting Senior Couple
Dividend Stocks

How Should Canadians Calculate the Perfect Retirement Income for Maximum Benefits

Here's how Canadians should calculate the perfect retirement income for maximum benefits.

Read more »

Train cars pass over trestle bridge in the mountains
Dividend Stocks

1 Canadian Railway Stock That’s Built for the Long Haul

A Canadian railway stock with solid growth fundamentals and a network that connects a continent is built for the long…

Read more »

Piggy bank on a flying rocket
Energy Stocks

The 6% Dividend Champion Built for Income Investors

Income investors seeking a great stock that can provide both growth and income over the longer term should strongly consider…

Read more »